Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

¼¼±âÁ¶Àý¹æ»ç¼±Ä¡·á¸¦ ½ÃÇà¹ÞÀº µÎ°æºÎ¾Ï ȯÀÚ±º¿¡¼­ ±¸°­°ÇÁ¶ÁõÁöÇ¥ ºÐ¼® Evaluation of Xerostomia Following Intensity Modulated Radiotherapy (IMRT) for Head and Neck Cancer Patients

´ëÇѹæ»ç¼±Á¾¾çÇÐȸÁö 2004³â 22±Ç 2È£ p.106 ~ 114
¼Ò¼Ó »ó¼¼Á¤º¸
À̼®È£/Lee SH ±èÅÂÇö/ÁöÀDZÔ/ÀÓÇö¼±/ÀÓÀº½Ç/·ùÁؼ±/Á¤À¯¼®/¹Ú¼º¿ë/±èÁÖ¿µ/ǥȫ·Ä/½Å°æȯ/±è´ë¿ë/Á¶°üÈ£

Abstract

¸ñ Àû: ¼¼±âÁ¶Àý¹æ»ç¼±Ä¡·á(IMRT)¸¦ ½ÃÇà¹ÞÀº µÎ°æºÎ¾Ï ȯÀÚ±º¿¡¼­ ±¸°­°ÇÁ¶Áõ ÁöÇ¥µéÀ» ÃøÁ¤½ÃÁ¡º°·Î ºñ±³ºÐ¼®ÇÏ°í ÀÌ ÁöÇ¥µé°ú ÀÌÇϼ±¿¡ Á¶»çµÈ ¹æ»ç¼±·®°úÀÇ ¿¬°ü¼ºÀ» ºÐ¼®ÇÏ°íÀÚ ÇÏ¿´´Ù.

´ë»ó ¹× ¹æ¹ý: 2003³â 2¿ùºÎÅÍ 10¿ù±îÁö µÎ°æºÎ¾ÏÀ¸·Î IMRT¸¦ ½ÃÇà¹ÞÀº 13¸íÀ» ´ë»óÀ¸·Î ÇÏ¿´´Ù. IMRT±ºÀÇ ¿¬·ÉÀº 43¢¦77¼¼(Áß¾Ó°ª 57¼¼)À̾ú°í, ±¸°­°ÇÁ¶ÁõÀ» Æò°¡ÇÏ´Â ÁÖ°üÀû ÁöÇ¥·Î¼­ 4Ç׸ñÀ¸·Î ±¸¼ºµÈ ±¸°­ÁöÇ¥Á¡¼ö(xerostomia questionnaire score: XQS)¿Í °´°üÀû ÁöÇ¥·Î¼­ ÀÚ±ØÀ¯¹«¿¡ µû¸¥ salivaÀÇ ºÐºñ·®(unstimulated & stimulated salivary flow rate: USFR & SSFR)À» ÃøÁ¤ÇÏ¿´°í, ÁÖ°üÀû ±×¸®°í °´°üÀû ÅëÇÕÁöÇ¥·Î¼­ LENT SOMA scale (LSC)À» ÃøÁ¤ÇÏ¿´´Ù. ÃøÁ¤½ÃÁ¡Àº Ä¡·á Àü, Ä¡·á ÈÄ 1°³¿ù, 3°³¿ùÀ̾ú´Ù. IMRT±º ³»¿¡¼­ Àüü ȯÀÚ±º°ú ÀüüÀÌÇϼ±¿¡ Á¶»çµÈ Æò±Õ¹æ»ç¼±·®À» ±âÁØÀ¸·Î ³ª´« µÎ ±º¿¡¼­ÀÇ ÃøÁ¤½ÃÁ¡¿¡ µû¸¥ ÁöÇ¥µé °£ º¯È­À¯¹«¸¦ º¸¾Ò°í, ³ª¾Æ°¡, ±¸°­°ÇÁ¶ÁõÁöÇ¥µé°ú Ÿ¾×ºÐºñ·® °£ÀÇ »ó°ü°ü°è¸¦ ºÐ¼®ÇÏ¿´´Ù.

°á °ú: IMRT±º Àüü13¸í ³»¿¡¼­ Ä¡·á Àü°ú Ä¡·á ÈÄ 1°³¿ù, 3°³¿ù¿¡ ÃøÁ¤µÈ XQS, LSC, USFR & SSFRÀº À¯ÀÇÇÑ º¯È­°¡ ¾ø¾î ±¸°­°ÇÁ¶ÁõÀÇ ¹ßÇöÀÌ °üÂûµÇÁö ¾Ê¾Ò´Ù. ÀüüÀÌÇϼ±¿¡ Á¶»çµÈ Æò±Õ¼±·® 3,500 cGy¸¦ ±âÁØÀ¸·Î ȯÀÚ±ºÀ» ³ª´©¾î º¸¾ÒÀ» ¶§, 3,500 cGy ¹Ì¸¸ Á¶»ç¹ÞÀº 8¸íÀÇ È¯ÀÚ±º¿¡¼­´Â À¯ÀÇÇÑ º¯È­°¡ ¾ø¾úÀ¸³ª 3,500 cGy ÀÌ»ó Á¶»ç¹ÞÀº 5¸íÀÇ È¯ÀÚ±º¿¡¼­´Â XQS, LSC, SSFR ±×¸®°í USFRÀÌ À¯ÀÇÇÏ°Ô Áõ°¡µÇ¾î ±¸°­°ÇÁ¶ÁõÀÇ ¹ßÇöÀÌ °üÂûµÇ¾ú´Ù. ¶ÇÇÑ, °¢ ÁöÇ¥µé°ú Ÿ¾×ºÐºñ·® °£ÀÇ »ó°ü°ü°è¸¦ º¸¾ÒÀ» ¶§, Ä¡·á ÈÄ 1°³¿ù°¿¡¼­ À¯ÀÇÇÑ »ó°ü°ü°è¸¦ º¸ÀÌÁö ¾Ê¾ÒÀ¸³ª, Ä¡·á ÈÄ 3°³¿ù°¿¡¼­ XQS, LSC°¡ Ä¿Áú¼ö·Ï USFR, SSFRÀÌ °¨¼ÒÇÏ´Â À¯ÀÇÇÑ »ó°ü°ü°è¸¦ º¸¿´´Ù.

°á ·Ð: º» ¿¬±¸°á°ú IMRT´Â ±¸°­°ÇÁ¶ÁõÀ» »ó´çÇÑ Á¤µµ·Î °¨¼Ò½Ãų ¼ö ÀÖ´Â °ÍÀ¸·Î ³ªÅ¸³µ°í, XQS¿Í LSCÀÌ À¯¿ëÇÑ ÀÓ»óÁöÇ¥·Î¼­ÀÇ °¡´É¼ºÀ» º¸¿´À½À» ¾Ë ¼ö ÀÖ¾ú´Ù. »îÀÇ ÁúÀ» ÀúÇÏÇÒ Á¤µµÀÇ ½ÉÇÑ ±¸°­°ÇÁ¶ÁõÀ» ÇÇÇϱâ À§Çؼ­´Â ¾çÃø ÀÌÇϼ± Àüü¿¡ Á¶»çµÇ´Â Æò±Õ¼±·®À» °¡´ÉÇÑ ÇÑ 3,500 cGy ¹Ì¸¸À¸·Î Á¶»çµÇµµ·Ï ÇÏ¿©¾ß ÇÒ °ÍÀ¸·Î »ý°¢ÇÑ´Ù. ÇâÈÄ, ÃæºÐÇÑ È¯ÀÚ¸¦ ´ë»óÀ¸·Î ÇÏ¿© ÀüüÀÌÇϼ±ÀÇ Æò±Õ¼±·®¿¡ ´ëÇÑ ½Å·ÚÇÒ ¼ö ÀÖ´Â °á°ú¿Í ³ª¾Æ°¡ Ÿ¾×ÀÇ ºÐºñ·®À» ´ë½ÅÇÒ ¼ö ÀÖ´Â ÀÓ»óÀûÁöÇ¥¸¦ ¼±Á¤ÇÏ´Â ¿¬±¸°¡ ÁøÇàµÇ¾î¾ß ÇÒ °ÍÀÌ´Ù.


Purpose: This study was done to evaluate xerostomia following intensity modulated radiotherapy for patients with head and neck cancer, and to analyze the correlation between the dosimetric parameters and xerostomia parameters.

Materials and Methods: From February till October 2003, 13 patients with 3 months of follow-up were evaluated for xerostomia after being treated for head and neck cancer with IMRT. Their median age was 57 years (range: 43¢¦77). Xerostomia were assessed with a 4-question xerostomia questionnaire score (XQS) and a test for salivary flow rates (unstimulated and stimulated). The patients were also given a validated LENT SOMA scale (LSC) questionnaire. The evaluations were completed before radiation therapy (pre-RT) and at 1 and, 3 months after radiation therapy (RT). We evaluated xerostomia at pre-RT, 1 and, 3 months after RT. The association between the xerostomia parameters (XQS and LSC) and salivary flow rates (unstimulated and stimulated: USFR and SSFR) was assessed at 1 and 3 months after RT.

Results: All 13 patients showed no significant changes in XQS, LSC and Salivary Flow rates. As a result, we couldn`t find out about xerostomia development. Based on the total mean parotid dose, 3,500 cGy, we divided these patients into two groups. The 8 patients (£¼3,500 cGy) showed no significant changes in XQS, LSC and Salivary Flow rates. However, in 5 patients (¡Ã3,500 cGy), there was a significant increase in USFR and, SSFR at 3 months after RT, and for the XQS and, LSC at 1 and 3 months after RT. The correlation between XQS and, LSC, and USFR and, SSFR in all patients (13) was significant at 3 months after RT. The correlation had a tendency to the decrease for USFR and, SSFR in proportion to the increase of XQS and, LSC.

Conclusion: Based on the results of this study, IMRT seem to be an effective treatment to significantly decrease the xerostomia. XQS and, LSC seem to be a effective tool for predicting the xerostomia. A total parotid gland mean dose of £¼3,500 cGy should be a planning goal if substantial sparing of the gland function is desired. Furthermore, patients should be enrolled in a study to define a more accurate threshold dose for the parotid gland.

Å°¿öµå

±¸°­°ÇÁ¶Áõ;ÀÌÇϼ±;Ÿ¾×ºÐºñ·®;¼¼±âÁ¶Àý¹æ»ç¼±Ä¡·á;Xerostomia;Parotid gland;Salivary flow rate;IMRT (Intensity modulated radiation therapy)

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS